MGRX Stock — Mangoceuticals, Inc. Common Stock

Mangoceuticals, Inc. Common Stock (MGRX)

Updated October 16, 2026.

MGRX is a Stock. Total return is -99.5% over the past 3.6 years, 199.3 points behind SPY at 99.8%.

Mangoceuticals, Inc. develops and sells men's wellness products through a telemedicine platform, offering erectile dysfunction treatments under the Mango brand, hair loss solutions under Grow, hormone therapies under Mojo, weight loss products under Slim, and oral testosterone replacement therapy under Prime, with online fulfillment through a licensed pharmacy. The company does not currently distribute to shareholders. This security may appeal to investors seeking exposure to the telehealth and men's health sectors, though the lack of distributions makes it oriented toward potential capital appreciation rather than income generation.

MGRX performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.5% over the past 3.6 years, 199.3 points behind SPY at 99.8%. Over the past year its total return — price change plus distributions reinvested — is -88.2%. Its deepest 1-year drawdown was 94.1%.

MGRX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/21/2023

Distribution frequency

None

Last close

$0.29 (as of 2026-10-16)

Market cap

$6,442,860

Average volume

262703.0

Beta

1.983

Payout ratio

0.0%

EPS

$-0.89

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MGRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 94.1%.

Who may consider MGRX — and who may not

It is a weaker fit for investors who need monthly cash flow (MGRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MGRX

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions